Showing results (161-170 of 234) with videos related to

Sort By:
Pageof 24
British Journal of Haematology|March 25, 2017
High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized StudyLoretta J Nastoupil, Peter McLaughlin, Lei Feng, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 29, 2019
Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell LymphomaStefan K Barta, Jasmine Zain, Alexander W MacFarlane, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2025
A Phase I Trial of Evorpacept, Lenalidomide and Rituximab for Patients with B-cell Non-Hodgkin LymphomaPaolo Strati, Lei Feng, Andrey Tyshevich, et al.
Haematologica|June 24, 2021
Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 studyAndrew M Evens, Joseph M Connors, Anas Younes, et al.
International Journal of Radiation Oncology, Biology, Physics|January 10, 2017
Chemotherapy Response Assessment by FDG-PET-CT in Early-stage Classical Hodgkin Lymphoma: Moving Beyond the Five-Point Deauville ScoreSarah A Milgrom, Wenli Dong, Mani Akhtari, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 12, 2016
Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin LymphomaPaolo Anderlini, Rima M Saliba, Celina Ledesma, et al.
British Journal of Haematology|August 3, 2021
Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analysesDaniel J Landsburg, Stefan K Barta, Radhakrishnan Ramchandren, et al.
British Journal of Haematology|July 23, 2016
Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic modelYiming Chen, Sattva Neelapu, Lei Feng, et al.
Nature Communications|August 7, 2025
Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trialPaolo Strati, Lei Feng, Jason R Westin, et al.
Blood|December 14, 2017
Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphomaSteven M Horwitz, Raphael Koch, Pierluigi Porcu, et al.
Pageof 24